Urolithin A Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Urolithin A dosing — protocols, safety, and where to buy.
Dosage Calculator
Calculate exact dosing for Urolithin A.
Dosing Protocols
Foundation protocol for urolithin A is designed for users new to mitochondrial optimization who want to integrate urolithin A into a basic longevity regimen with minimal complexity and cost. This protocol captures most of the functional benefit demonstrated in clinical trials while remaining accessible to a broad user base.
Pre-start assessment: Before starting, confirm no absolute contraindications (active pregnancy planning, specific medical concerns that warrant physician input). Baseline measurements are optional but helpful: note current exercise capacity (can you comfortably do typical daily activities? how far can you walk at brisk pace before fatigue?), track recovery time after exercise, note any existing muscle/joint symptoms, record general energy and cognitive baseline. These subjective baselines will help you assess whether urolithin A produces noticeable effects over months of use.
Product selection: For foundation-level use, reasonable product options include (a) Mitopure (Timeline Nutrition's commercial urolithin A, with the strongest clinical evidence backing its specific formulation); (b) generic urolithin A from reputable supplement brands that conduct third-party testing. Prefer capsule or softgel formulations over powder. Verify products are within appropriate shelf life and stored properly. Expect to pay $20-80 monthly depending on product selection and dose.
Weeks 1-2 (gentle introduction): Start at 250-500 mg daily with a meal containing some fat. This entry dose allows tolerability assessment and gradual adaptation. Track any subjective effects during this introduction period. Most users experience no noticeable acute effects; this is normal and does not mean the compound is not working. If mild GI effects occur, continue with meals or split the dose between morning and evening.
Weeks 3-8 (standard dose establishment): Increase to 500-1000 mg daily. Most clinical trial evidence supports 500-1000 mg as the functional dose range; users can start at 500 mg and potentially increase to 1000 mg based on individual response and budget. Continue taking with a meal. Maintain consistent daily timing for routine compliance. Continue tracking subjective markers.
Weeks 8-16 (outcome assessment): At the 2-4 month mark, assess whether you notice beneficial effects. Common subjective signals include: better exercise recovery (less post-workout fatigue, faster return to baseline), somewhat improved energy during day-to-day activities, subtle improvements in muscle performance or resilience, possibly improved sleep quality. None of these are guaranteed or dramatic. Users experiencing clear benefit may continue confidently. Users not perceiving benefit should consider whether continuation is worth the cost or whether different interventions might be more productive.
Months 4-12 (continuation): Continue at established dose indefinitely if desired. No evidence supports or refutes cycling urolithin A (taking breaks from use); most users take it continuously for practical reasons. Periodic (every 6-12 months) reassessment of whether continued use remains worthwhile is appropriate.
Foundation dose: 250-500 mg daily for first 2 weeks, then 500-1000 mg daily long-term, with a meal (morning or midday preferred for routine). Simple oral administration, no injection required, no reconstitution required. Well-tolerated for most users without special precautions. This foundation protocol captures most of the clinical trial benefit with minimal complexity and is appropriate as a standalone intervention or as one element of a broader longevity stack.
Intermediate protocol for urolithin A assumes the user has established tolerability on a foundation protocol and wants to pursue sustained mid-level mitochondrial optimization as part of a broader longevity stack. This level integrates urolithin A with several complementary interventions while maintaining accessibility.
Dosing: 1000 mg urolithin A daily, taken with a meal. Split dosing (500 mg morning + 500 mg evening) is acceptable if preferred, though once-daily dosing is simpler and pharmacokinetically adequate given urolithin A's half-life. Timing is flexible; pick a consistent daily routine (for example, with breakfast every day) for compliance.
Integrated mitochondrial foundation stack: Layer urolithin A onto a core mitochondrial support regimen:
- Urolithin A 1000 mg daily
- NMN 500 mg daily (morning, with or without food)
- Ubiquinol (CoQ10) 200 mg daily (with fat-containing meal for absorption)
- Creatine monohydrate 5 g daily (with any meal or post-exercise)
- Omega-3 (EPA + DHA) 2-3 g daily (with meal)
- Vitamin D3 (dose based on blood level, typically 2000-5000 IU)
- Magnesium 400 mg daily (glycinate or threonate forms for tolerability)
This integrated stack addresses mitochondrial biology from multiple angles: quality control (urolithin A), NAD+ supply (NMN), electron transport cofactor (CoQ10), energy buffering (creatine), membrane composition (omega-3), and foundational micronutrients. Monthly cost for this stack ranges from $80-200 depending on product selection and doses.
Exercise integration: Consistent exercise is the most potent mitochondrial intervention available and is foundational rather than optional at the intermediate level. Aim for aerobic exercise 3-5 times weekly (150-300 minutes moderate intensity per week, or 75-150 minutes vigorous intensity) + resistance training 2-3 times weekly covering major muscle groups. Urolithin A supports recovery from this exercise and complements exercise-induced mitochondrial adaptation.
Dietary considerations: Prioritize whole foods, adequate protein (1-1.6 g/kg body weight/day for muscle maintenance), varied vegetables and fruits (including pomegranate, walnut, and berry sources of ellagitannins that support broader polyphenol intake), and adequate hydration. Consider time-restricted eating (12-14 hour overnight fasting window) for added mitochondrial benefit through autophagy induction; this combines naturally with urolithin A's mitophagy effects.
Sleep optimization: Target 7-9 hours of consistent sleep nightly. Sleep is essential for mitochondrial biogenesis, autophagy, and general cellular repair. Supplements cannot substitute for adequate sleep.
Monitoring and adjustment: Track subjective measures monthly (energy, exercise recovery, muscle performance, general well-being). Check basic laboratory parameters annually (comprehensive metabolic panel, CBC, lipid panel, vitamin D, hs-CRP) as part of general health maintenance rather than specifically tied to urolithin A. Adjust protocol based on tolerability and perceived benefit.
Long-term perspective: Intermediate protocol is designed for indefinite use, with periodic (6-12 month) reassessment of individual components and their continued value. Users may rotate specific supplements in and out based on changing goals or emerging evidence, but urolithin A as the core mitophagy intervention typically remains constant.
Cost considerations: Intermediate protocol cost varies widely by product selection. Mitopure (Timeline's premium product) is more expensive than generic urolithin A but has the strongest direct clinical evidence. Users can choose based on budget; generic products from reputable brands with third-party testing are reasonable cost-conscious alternatives.
Intermediate protocol dose: 1000 mg urolithin A daily as part of integrated mitochondrial foundation stack (NMN + CoQ10 + creatine + omega-3 + vitamin D + magnesium) + consistent exercise + sleep optimization + quality diet. This intermediate protocol represents the mainstream committed longevity stack for users pursuing sustained mitochondrial optimization without moving to advanced peptide interventions.
Advanced protocol for urolithin A integrates the compound into a comprehensive longevity stack that includes peptide interventions, prescription medications (under appropriate medical supervision), and advanced monitoring. This protocol is appropriate only for users with extensive longevity practice experience, access to specialist physicians, and willingness to commit substantial resources.
Core dosing: 1000-1500 mg urolithin A daily. Doses above 1000 mg have been used in some clinical trials (up to 2000 mg in phase 1 safety studies) without additional safety concerns, and advanced users may use higher doses if they perceive benefit differences. Evidence for superior efficacy above 1000 mg is modest; most of the benefit appears to plateau near 500-1000 mg in clinical trials.
Integration with mitochondrial peptide stack: Advanced protocols often combine urolithin A with mitochondrial peptides:
- Urolithin A 1000-1500 mg daily (oral)
- SS-31 (elamipretide) 20-40 mg subcutaneous daily or most days weekly
- MOTS-c 5-10 mg subcutaneous 2-3 times weekly
- Humanin 5-10 mg subcutaneous 2-3 times weekly
- NMN 500-1000 mg daily
- Ubiquinol 200-300 mg daily
- Creatine 5 g daily
- Omega-3 2-3 g EPA/DHA daily
- Other foundational micronutrients
This comprehensive stack addresses multiple aspects of mitochondrial biology simultaneously: mitophagy (urolithin A), inner membrane stability (SS-31), metabolic signaling (MOTS-c, humanin), NAD+ supply (NMN), electron transport cofactor (CoQ10), energy buffering (creatine), and membrane composition (omega-3). Monthly cost for the peptide-inclusive stack ranges from $500 to over $2000 depending on product selection, which is a significant resource commitment.
Prescription medication integration (physician-supervised): Some advanced longevity protocols integrate prescription medications under specialist medical supervision:
- Rapamycin (sirolimus) at longevity doses (3-6 mg weekly)
- Metformin or other insulin-sensitizing agents
- Low-dose aspirin (if cardiovascular risk warrants)
- Statins or other lipid-modifying agents (if indicated)
- Hormone replacement therapy (if age and symptom-appropriate)
These prescription components require physician partnership, appropriate monitoring, and individualized indication review. Urolithin A integrates without significant interaction concerns with these medications, but overall regimen complexity increases monitoring burden.
Advanced monitoring: Quarterly or semi-annual laboratory panels including comprehensive metabolic panel, CBC, lipid panel, hs-CRP, fasting insulin and HbA1c, liver function tests, kidney function with cystatin C (more accurate in aging), vitamin D, homocysteine, and relevant domain-specific markers (testosterone if on TRT, NT-proBNP if cardiac concerns, etc.). Specialized testing (mitochondrial function assays in research contexts, epigenetic age measurement, cardiac imaging, cognitive assessment) may supplement basic labs for advanced users.
Biomarker-driven optimization: Some advanced users use biomarker panels to optimize their stack, adjusting components based on measured changes. For example, if hs-CRP remains elevated despite the core stack, adding additional anti-inflammatory interventions; if exercise recovery remains suboptimal, intensifying mitochondrial support; if sleep metrics show deterioration, prioritizing sleep optimization interventions. This approach requires access to laboratory testing and appropriate interpretation.
Exercise at advanced level: Advanced longevity practitioners typically maintain serious exercise programs — multiple hours of structured exercise weekly, progressive resistance training with appropriate periodization, cardiovascular training across intensity spectrum (including high-intensity interval training for mitochondrial biogenesis), and sport-specific or movement-quality-focused work. Exercise is non-negotiable at this level; urolithin A supports but does not substitute.
Diet and nutrition: Advanced protocols typically include detailed nutritional strategy: high-quality protein at adequate amounts (1.2-1.6 g/kg body weight daily), varied polyphenol-rich vegetables and fruits (including ellagitannin sources that support endogenous urolithin production in high converters), quality fats emphasizing olive oil, fish, nuts, omega-3 sources, reduced ultra-processed food intake, time-restricted eating or periodic fasting as tolerated, and careful attention to micronutrient adequacy.
Periodic regimen reviews: Every 6-12 months, review the entire stack with a longevity-specialist physician. Assess: which components are producing clear value? Which are costing substantially without clear benefit? What emerging evidence suggests modifications? What should be added, dropped, or adjusted? This ongoing optimization is essential at the advanced level because the longevity field evolves rapidly and strategies should evolve accordingly.
Ethical and psychological considerations: Advanced longevity practice requires psychological balance. Obsession with optimization can itself produce stress that offsets intervention benefits. Maintaining perspective (most benefit comes from foundational behaviors), avoiding perfectionism (any reasonable protocol is sufficient for most users), and retaining joy in life outside optimization are all important. Advanced protocols should serve life satisfaction rather than dominating it.
Advanced protocol dosing and structure: 1000-1500 mg urolithin A daily within a comprehensive mitochondrial stack (peptides + precursors + cofactors + substrates) integrated with prescription longevity medications under physician supervision, serious exercise and nutritional strategy, advanced monitoring through regular labs and biomarkers, and periodic regimen optimization. Appropriate only for users with extensive longevity experience, specialist physician partnership, and resources to support comprehensive intervention. Monthly cost for advanced stack ranges $500-$2000+ depending on peptide inclusion and prescription components.
Commonly Stacked With
Urolithin A stacks naturally with the broader ecosystem of mitochondrial and longevity interventions, and its specific mechanism (mitophagy induction) makes it complementary rather than redundant with most other mitochondrial compounds. A well-designed mitochondrial longevity stack addresses multiple aspects of mitochondrial biology — biogenesis, substrate supply, membrane integrity, quality control, signaling — and urolithin A specifically fills the quality control niche that many other interventions do not address directly.
NMN / NR (NAD+ precursors): NMN and nicotinamide riboside elevate cellular NAD+, supporting sirtuin activity, mitochondrial biochemistry, and DNA repair. Combined with urolithin A's mitophagy effects, the mechanisms are strongly complementary: NAD+ supports the activity of existing mitochondria, urolithin A clears damaged ones and supports turnover. This combination is widely used in longevity protocols. Typical stacking: NMN 250-1000 mg daily + urolithin A 500-1000 mg daily.
CoQ10 / ubiquinol: CoQ10 is an essential electron transport chain cofactor and mitochondrial antioxidant. It supports the function of existing mitochondria; urolithin A clears damaged ones. Complementary mechanisms with no significant interaction concerns. Typical stacking: 100-300 mg ubiquinol daily + urolithin A.
SS-31 (elamipretide): SS-31 stabilizes cardiolipin on the inner mitochondrial membrane, preserving the integrity of existing mitochondria. Urolithin A clears damaged mitochondria. The combination provides comprehensive mitochondrial support: preserve the good (SS-31), clear the bad (urolithin A), build new ones (exercise, biogenesis stimuli). This is an increasingly common advanced stacking approach. Cost is significant; the benefit of both compared to either alone has not been rigorously quantified but mechanistic complementarity supports the combination.
MOTS-c and humanin: MOTS-c and humanin are mitochondrial-derived peptides with signaling effects on insulin sensitivity, neuroprotection, and metabolic health. Mechanisms are distinct from urolithin A's mitophagy effects; combinations provide broader mitochondrial-relevant coverage.
Creatine: Creatine buffers cellular ATP through the phosphocreatine-creatine kinase system, supporting high-energy-demand tissues (muscle, brain). Mechanism is complementary to urolithin A — creatine addresses cellular energy buffering, urolithin A addresses mitochondrial quality control. Safe to stack; commonly combined in muscle-focused protocols.
Omega-3 fatty acids (EPA/DHA): EPA and DHA are incorporated into mitochondrial membranes and modulate inflammatory resolution. Complementary to urolithin A; commonly stacked.
Rapamycin: Rapamycin inhibits mTORC1, promoting autophagy and mitophagy through distinct but overlapping mechanisms. Urolithin A's specific mitophagy effects may complement rapamycin's broader autophagy induction. Weekly rapamycin combined with daily urolithin A is a reasonable pattern for users pursuing advanced longevity protocols under physician supervision.
Fisetin and senolytics: Fisetin clears senescent cells; urolithin A supports quality control of remaining healthy cells' mitochondria. Complementary mechanisms without direct overlap. Periodic fisetin pulses plus daily urolithin A is a common pattern.
Curcumin and other polyphenols: Curcumin, resveratrol, and other anti-inflammatory polyphenols complement urolithin A through distinct mechanisms (NF-κB inhibition, Nrf2 activation, direct antioxidant effects). Safe stacking; additive anti-inflammatory coverage.
NAC (N-acetylcysteine): NAC supports glutathione synthesis and provides broad antioxidant and hepatoprotective coverage. Complementary to urolithin A. Safe stacking.
Metformin: Metformin has multiple mitochondrial-relevant effects including complex I modulation, AMPK activation, and indirect mitophagy induction through AMPK signaling. Combinations with urolithin A have theoretical synergy on mitophagy; safe stacking without specific interaction concerns. Note metformin requires prescription and has separate indications and considerations.
Exercise: Regular aerobic and resistance exercise is the most potent mitochondrial biogenesis stimulus available, upregulating PGC-1α and creating new mitochondrial content. Exercise also directly induces mitophagy through similar mechanisms as urolithin A. Rather than being redundant, the combination supports both biogenesis (exercise-induced) and quality control (urolithin A-enhanced). Users committed to mitochondrial health should prioritize exercise as foundational and add urolithin A as supportive.
Caloric restriction and time-restricted eating: Caloric restriction protocols activate AMPK, inhibit mTOR, induce autophagy and mitophagy, and produce many mitochondrial benefits similar to pharmacological mitochondrial interventions. Combining caloric restriction with urolithin A supplementation provides complementary and potentially additive mitochondrial support.
B-vitamins and mitochondrial nutrients: B-vitamin complex, carnitine, lipoic acid, and other mitochondrial-supportive nutrients form the foundation of many mitochondrial support protocols. Urolithin A complements these as a specific mitophagy enhancer. Safe stacking.
Vitamin D, magnesium, zinc: Foundational micronutrients that should be optimized regardless of additional supplementation. No specific interactions with urolithin A.
What not to stack: Avoid using urolithin A as a substitute for exercise, which remains the most potent mitochondrial intervention available. Avoid using urolithin A as a substitute for evidence-based treatments for diagnosed medical conditions. Avoid overlapping stacking of multiple mitophagy-inducing compounds beyond established protocols — the incremental benefit is unclear, and cumulative mitophagy stimulation may have unknown consequences at extreme levels.
Stacking with natural food sources: Dietary consumption of ellagitannin-rich foods (pomegranates, walnuts, berries) provides additional polyphenol intake and supports endogenous urolithin production in high-converter individuals. Consumption of these foods does not substitute for urolithin A supplementation in non-converters, but adds supportive nutritional context.
Foundation urolithin A-centered mitochondrial stack example: Daily urolithin A 500-1000 mg + NMN 500 mg + ubiquinol 200 mg + creatine 5 g + omega-3 2 g EPA/DHA + vitamin D (to adequate blood level) + magnesium 400 mg + exercise (aerobic 3-5x/week, resistance 2-3x/week) + adequate sleep and nutrition. This foundation stack provides comprehensive mitochondrial support at moderate cost and is appropriate for broad use. Advanced additions (SS-31, rapamycin, fisetin) can be layered for users pursuing more intensive intervention.
Side Effects & Safety
Contraindications
Urolithin A has a favorable contraindication profile compared to most longevity interventions. Absolute contraindications are limited; relative contraindications warrant physician input in specific situations. Overall, urolithin A is one of the safer entries in the longevity supplement space. Pregnancy: Urolithin A supplementation is not recommended during pregnancy. Dietary exposure from ellagitannin-containing foods is safe by long history, and endogenous urolithin production occurs in pregnant women who are natural converters. However, concentrated supplemental dosing during pregnancy has not been adequately studied, and the precautionary principle argues for avoidance. Women of reproductive potential who become pregnant while supplementing should typically discontinue. Lactation: Urolithin A supplementation is not recommended during breastfeeding. Whether the compound transfers into breast milk in meaningful quantities is not established. Dietary exposure from fruits is acceptable; supplemental dosing is avoided in the absence of specific safety data. Pediatric use: Urolithin A supplementation is not recommended for children under 18. No pediatric safety or dosing data exist outside research contexts. Dietary ellagitannin intake through fruits is obviously safe and appropriate for children. Active cancer: Patients with active malignancy should discuss urolithin A supplementation with their oncologist before starting. Preclinical data suggest urolithin A may have anti-cancer effects in some contexts, but effects on established cancers receiving active treatment are context-dependent and potentially variable. Most oncologists prefer to avoid adding supplemental bioactive compounds during active treatment unless part of a specific research protocol. Cancer in remission may allow use but still warrants oncology discussion. Primary mitochondrial disease: Patients with primary mitochondrial diseases should discuss urolithin A with their mitochondrial specialist. The compound's mitophagy-inducing mechanism is mechanistically interesting for many mitochondrial conditions, but specific disease contexts may have individualized considerations. Effects on mtDNA heteroplasmy (theoretical shifts in the ratio of mutant to wild-type mitochondrial DNA) could be beneficial or detrimental depending on disease and tissue context; this is a theoretical rather than documented concern, but warrants specialist input. Active hepatic or renal disease: Urolithin A pharmacokinetics in severe hepatic or renal impairment have not been extensively characterized. Users with well-compensated chronic liver or kidney disease may reasonably use urolithin A at standard doses; those with severe or decompensated disease should consult their physician and approach with caution. Known allergy: Rare allergic reactions to urolithin A or to excipients in specific products have been reported. Users with documented allergies to specific ingredients in commercial products (gelatin, soy, specific oils in softgels) should check formulations and switch products if needed. Anticoagulant therapy: Urolithin A has minimal antiplatelet activity compared to many polyphenols. Specific interactions with anticoagulants (warfarin, DOACs) or antiplatelet agents (aspirin, clopidogrel) are unlikely to be clinically significant, but users on these medications should discuss new supplement additions with their prescribing physician as general practice. Surgery and perioperative: Most protocols recommend discontinuing urolithin A 1-2 weeks before major elective surgery as part of general supplement discontinuation guidance. Specific urolithin A perioperative data are not available, so the recommendation is conservative. Resume after recovery. Autoimmune disease: Urolithin A's immunomodulatory effects are incompletely characterized. Users with active autoimmune disease on immunomodulator therapy should discuss with their rheumatologist. No specific interactions have been documented, but individualized review is appropriate for users on complex immunomodulatory regimens. Active investigational research: Users participating in clinical trials should disclose all supplements to trial investigators; most protocols prohibit concurrent supplementation that could confound results. Specific medication considerations: Urolithin A has minimal documented pharmacokinetic interactions, with limited effects on CYP450 enzymes at typical supplement doses. Users on narrow-therapeutic-index drugs should still discuss with their pharmacist or physician, but urolithin A-specific interaction concerns are minimal. Individual sensitivities: A small percentage of users may have idiosyncratic responses (persistent GI effects, unexplained fatigue, rash). These users should discontinue and consider alternative mitochondrial support strategies. Cost considerations as "contraindication": While not a medical contraindication, users with limited financial resources should honestly evaluate whether ongoing urolithin A cost fits within their budget. Foundational health behaviors (exercise, sleep, nutrition) produce greater benefit than any supplement and are not affected by financial constraints. Over-reliance concern: Urolithin A should supplement, not substitute, foundational health behaviors. Users who view urolithin A as a "magic pill" substitute for exercise or sleep will be disappointed and may fail to pursue more impactful interventions. This is a framing concern rather than a medical contraindication. When physician consultation is appropriate before starting urolithin A: Users with 3 or more chronic prescription medications, users with complex chronic disease, users with active or historical cancer, users on immunomodulators, users with advanced organ dysfunction, users in active clinical research, women planning pregnancy or breastfeeding. For most otherwise-healthy adults, urolithin A can be started without specific medical clearance, though periodic physician wellness visits remain good practice. Summary contraindication position: Urolithin A is among the safer longevity interventions available, with no absolute contraindications in otherwise-healthy adults and limited relative contraindications in specific populations. The favorable safety profile, GRAS status, and mainstream availability make urolithin A appropriate for broad mainstream use, with ordinary attention to individual circumstances and physician consultation when specific concerns apply.
Additional Notes
Urolithin A oral dosing is straightforward, with dose ranges of 250-1500 mg daily supported by clinical trial evidence and consumer experience. Dosing guidance below covers the practical questions: how much, how often, with or without food, morning or evening, and how to adjust based on individual response.
Standard functional dose: 500-1000 mg daily. This range encompasses the doses used in most phase 2 clinical trials (Liu 2022 used 1000 mg daily; other trials have used 500 mg) and appears to capture most of the biological effect. Users targeting clinical-trial-equivalent exposure should use 500-1000 mg daily.
Starting dose for new users: 250-500 mg daily for the first 1-2 weeks, allowing assessment of tolerability and gradual adaptation. Most users tolerate starting at full dose without issue, but the gradual introduction is a conservative approach with minimal downside.
Intermediate and advanced doses: 1000-1500 mg daily for users pursuing more intensive protocols. Evidence for doses above 1000 mg is more limited, and incremental benefit is unclear.
Maximum studied dose: 2000 mg daily was used in phase 1 safety studies (Andreux 2019) without dose-limiting toxicity. Most users do not need to reach this dose; the 500-1000 mg range captures most functional benefit.
Timing of daily dose: Once daily dosing is sufficient based on urolithin A's 8-12 hour plasma half-life. Morning administration with breakfast is most common and practical. Evening administration is acceptable if preferred. Users who prefer split dosing (500 mg morning + 500 mg evening, for example) can do so with minimal difference in expected effect.
With food versus empty stomach: Taking urolithin A with food is preferred for three reasons: (1) moderately improved absorption due to lipophilic character of the compound; (2) better gastrointestinal tolerability; (3) routine integration with daily meals for compliance. Empty-stomach dosing is acceptable but not recommended as default practice.
Fat-containing meals: Because urolithin A has lipophilic character, meals containing some fat support better absorption than carbohydrate-only or fat-free meals. Examples of supportive meals: breakfast with eggs, cheese, or avocado; lunch with olive oil dressing or fatty fish; dinner with nuts or meat. Low-fat meals still support absorption adequately for practical purposes.
Adjusting dose based on response: Users who perceive clear benefit at 500 mg can stay at that dose indefinitely. Users who want to test higher doses can try 1000 mg for 4-8 weeks and assess whether incremental benefit is noticeable. Users who do not perceive benefit at 1000 mg after 3-6 months may reasonably discontinue rather than escalating further.
Cycling considerations: No evidence supports cycling urolithin A (taking periodic breaks). Most clinical trials used continuous daily dosing. Some users prefer to cycle for psychological reasons (avoiding feeling "dependent") or for budget management, but cycling is not biologically required.
Missed doses: If you miss a dose, simply take the next scheduled dose; do not double-up. Occasional missed doses have minimal impact on overall protocol effect given the compound's moderate half-life.
Adjusting for body weight: Clinical trials have used fixed doses rather than weight-adjusted doses. For very small adults (under 50 kg) or very large adults (over 110 kg), some adjustment may be reasonable: 500 mg daily for smaller adults, 1000-1500 mg for larger adults. Most adults fit in the 500-1000 mg range regardless of body weight.
Duration of use: Urolithin A is designed for long-term continuous use. Clinical trials have extended to 4 months of continuous use; consumer experience extends to multiple years. No evidence suggests limiting duration.
Special populations: Older adults (over 65), individuals with sarcopenia, those with limited exercise capacity, and those with specific mitochondrial concerns may benefit from higher doses (1000-1500 mg) within the standard range. Younger healthy adults without specific concerns can reasonably use 500 mg.
Product-specific dose equivalence: Different commercial products may use slightly different purity standards or formulation strategies. Mitopure (Timeline) is the premium product with the strongest direct clinical evidence; dose guidance aligns directly with clinical trial dosing. Generic urolithin A products from reputable manufacturers (supplement companies with third-party testing) are reasonable alternatives at similar dose amounts; generic products with unclear sourcing may have variable actual content and should be approached cautiously.
Quality verification: For product quality assurance, prefer brands that: (1) publish third-party certificate of analysis documenting identity and purity; (2) have established supplement industry track records; (3) provide clear sourcing information. Extremely low-priced products from obscure brands may have quality issues.
Interaction with endogenous production: Users who are natural high converters (producing urolithin A endogenously from dietary ellagitannins) already have some exposure from diet. For these users, supplementation provides more consistent and typically higher exposure than diet alone. For non-converters (the majority), supplementation is the only practical route to meaningful urolithin A exposure. There is no harm in combining dietary ellagitannin intake (pomegranate, walnut, berry consumption) with supplementation — dietary intake provides broader polyphenol benefit beyond urolithin A alone.
Food sources of ellagitannins (dietary pathway): While not a substitute for supplementation in most users, dietary ellagitannin sources include pomegranate (juice, seeds, molasses), walnuts, strawberries, raspberries, blackberries, oak-aged red wine (small amounts), aged spirits (small amounts), and some teas. Consuming these foods regularly supports broader health through polyphenol intake regardless of individual urolithin A conversion capacity.
Storage: Store urolithin A capsules/softgels in original container, tightly closed, in a cool dry place away from direct light and heat. Typical shelf life is 2 years from manufacture. Use within manufacturer's stated expiration. Refrigeration is not required but does not harm stability.
Summary of optimal dosing: 500-1000 mg once daily with a meal (morning preferred), continuous use, with a meal for better absorption and tolerability. Adjust within the 250-1500 mg range based on individual response, goals, and budget. This simple dosing protocol captures clinical trial benefit and integrates easily into daily routines.
Frequently Asked Questions
What is the recommended Urolithin A dosage?
Dosage for Urolithin A varies by protocol. Consult a qualified healthcare provider.
How often should I take Urolithin A?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Urolithin A need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Urolithin A side effects?
Urolithin A has an exceptionally favorable safety profile among longevity-relevant interventions, reflecting both its status as a naturally occurring gut-microbiome metabolite found in human bloodstream from ellagitannin-containing foods and deliberate clinical development studies documenting safety at doses substantially above typical consumer use. For most users, urolithin A is among the safest serious mitochondrial interventions available, though as with any bioactive compound, individual sensitivities and theoretical concerns warrant attention. Clinical trial safety record: Multiple phase 1 and phase 2 trials have evaluated urolithin A at doses ranging from 250 mg to 2,000 mg daily for periods up to 4 months. Adverse event rates have generally been low and balanced between urolithin A and placebo groups. The phase 1 study by Andreux et al.established an acceptable safety profile up to 2,000 mg daily in healthy older adults, with no dose-limiting toxicities identified. Subsequent phase 2 trials have reinforced this safety picture. Laboratory parameters (comprehensive metabolic panel, complete blood count, liver function, kidney function) have remained stable across trials. Common mild effects: The most commonly reported potential side effects are mild gastrointestinal symptoms — occasional abdominal discomfort, bloating, or changes in bowel habits in a minority of users. These are typically mild, transient, and self-limited, often resolving after 1-2 weeks of continued use as the gastrointestinal system adapts. Taking urolithin A with food (as recommended) reduces these effects further. Severe or persistent GI effects are uncommon and generally resolve with discontinuation. Fatigue or energy changes: A small subset of users report transient fatigue or sleep changes during the first 1-2 weeks of supplementation, possibly reflecting adaptation to altered mitochondrial turnover dynamics or simply placebo-adjacent individual responses. These effects are typically mild and self-limited; persistent fatigue without resolution warrants evaluation for other causes. Headache: Rare reports of mild headache with urolithin A supplementation. Usually self-limited; may resolve with continued use or after brief discontinuation. Rare skin reactions: Rare cases of skin reactions (mild rash, pruritus) have been reported anecdotally. These may reflect allergic responses to other ingredients in specific commercial products (fillers, capsule components) rather than urolithin A itself. Users with such reactions should try different product formulations to identify whether the reaction is specific to urolithin A or to accompanying excipients. Effects on energy metabolism: Theoretical concerns about effects on energy metabolism with chronic mitophagy enhancement have not materialized in clinical data. Some users may experience subtle shifts in exercise recovery, sleep patterns, or energy partitioning — these are usually favorable but occasionally require adjustment. Interactions with medications: Urolithin A has minimal documented pharmacokinetic interactions. It does not significantly inhibit or induce CYP450 enzymes at standard doses, reducing concerns about drug interactions compared to many polyphenolic supplements. Users on narrow-therapeutic-index drugs should still discuss new supplement additions with their pharmacist or physician, but urolithin A-specific interaction concerns are minimal. Mitochondrial disease considerations: Patients with primary mitochondrial diseases should discuss urolithin A with their mitochondrial specialist physician before starting. The mechanism (enhanced mitophagy) is theoretically attractive for many mitochondrial conditions, but specific disease contexts may require individualized evaluation. Some conditions involving mtDNA heteroplasmy might theoretically be affected by mitophagy modulation (potentially shifting heteroplasmy ratios favorably or unfavorably depending on specific disease and tissue context); the practical significance of this is unclear and warrants specialist input. Pregnancy and lactation: Urolithin A supplementation data in pregnancy and lactation are limited. Dietary ellagitannin exposure (pomegranate, walnut, berry consumption) has been safe by long historical observation, and endogenous urolithin production from dietary sources occurs naturally in many pregnant women without known harm. However, concentrated supplemental dosing during pregnancy or lactation has not been studied adequately, and most manufacturers recommend avoiding supplementation during these periods in the absence of specific evidence-based rationale. Women of reproductive potential who become pregnant while supplementing should typically discontinue pending specialist consultation. Pediatric use: Urolithin A supplementation in children has not been studied adequately and is not recommended for pediatric use outside specific research contexts. Dietary ellagitannin exposure through fruit consumption is obviously safe and appropriate for children. Anticoagulant and antiplatelet therapy: Urolithin A has minimal antiplatelet activity relative to many polyphenols, but general caution with any bioactive supplement in users on anticoagulation is appropriate. No specific interactions have been documented, but users on warfarin, DOACs, or antiplatelet therapy should discuss with their prescribing physician. Cancer considerations: Preclinical data suggest urolithin A may have anti-cancer effects in specific contexts, but may also have context-dependent effects on cell proliferation and apoptosis. Users with active cancer should discuss supplementation with their oncologist before starting. Patients in cancer remission may have more flexibility but should still coordinate with their oncology team. Surgery: Most protocols suggest discontinuing urolithin A 1-2 weeks before elective surgery as general supplement discontinuation guidance, resuming after recovery. Specific urolithin A surgical interaction data are not available, so the guidance is conservative rather than evidence-based. Research peptide quality concerns (applicable to other compounds, less so here): Unlike SS-31 or MOTS-c, urolithin A supplements are generally available through mainstream channels (Amazon, supplement retailers, commercial brands) rather than through research chemical suppliers. This makes product quality concerns less acute than for peptides obtained through unregulated suppliers. Still, quality varies among commercial products — prefer reputable brands with third-party testing (Mitopure from Timeline, or established supplement companies that test product identity and purity) over generic products with unclear sourcing. Long-term safety: Clinical trial data extend to 4 months with excellent safety. Dietary exposure has been safe by long history, and endogenous production in high-converter individuals provides human exposure data at low-to-moderate levels over lifetimes. Long-term consumer use at supplemental doses has occurred for several years with post-market experience favorable. Theoretical long-term concerns are limited; continued monitoring as use extends is prudent but no specific warnings have emerged. When to stop urolithin A: Discontinue and seek medical evaluation for severe GI symptoms, rash or allergic reactions, unexpected systemic symptoms, or any concerning new finding during supplementation. Most users experience no adverse effects and continue protocols indefinitely without incident. Users not perceiving benefit after 3-6 months of consistent use may reasonably discontinue based on cost-benefit considerations. Risk-benefit framing: Urolithin A combines strong mechanistic rationale, solid clinical evidence base, excellent safety profile, GRAS status, reasonable cost, and convenient oral administration. For most users interested in mitochondrial health support, urolithin A is among the more defensible choices in the longevity supplement space. The risk profile compares favorably to riskier or less-supported interventions, making it appropriate for mainstream use.
Where can I buy Urolithin A?
Visit our vendor directory to find trusted sources for Urolithin A.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
